Company intelligence / Profile preview

Skin

Manchester, Greater Manchester, United Kingdom

Ownership: Private
Employees: ~20
Development stage: Other

Overview

SkinBioTherapeutics is a life sciences company focused on harnessing the power of the human microbiome to improve skin health. The company's proprietary platform, SkinBiotix, utilizes lysates derived from probiotic bacteria to enhance the skin's barrier function, protect against infection, and promote regeneration. Their lead commercial product, AxisBiotix-Ps, is a food supplement designed to manage the symptoms of psoriasis from the inside out. Beyond dermatology, the company is exploring applications in infection control and advanced wound care through strategic partnerships.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Live biotherapeutic product therapyMicrobial therapyProteinPeptides
Industry: Biotech

Partnerships

Croda InternationalWinclove ProbioticsSederma

Beyond the preview

Go deeper on Skin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skin.

Explore the full profile